CATX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

211.42K

-9.65%

-0.365

-40.23%

147.00K

-57.02%

-0.382

+52.67%

125.00K

-56.9%

-0.363

+25.29%

Estimates Revision

The market is revising Downward the revenue expectations for Perspective Therapeutics, Inc. (CATX) for FY2025, with the revenue forecasts being adjusted by -5.22% over the past three months. During the same period, the stock price has changed by -41.56%.

Revenue Estimates for FY2025

Revise Downward

-5.22%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.01%

In Past 3 Month

Stock Price

Go Down

-41.56%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast CATX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CATX is 11.40 USD with a low forecast of 5.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

11.40

High

18.00

Current: 0.000

Low

5.00

Averages

11.40

High

18.00

Truist

NULL -> Buy

initiated

$8 -> $12

2025-11-24

Reason

Truist

Price Target

$8 -> $12

2025-11-24

initiated

NULL -> Buy

Reason

Truist assumed coverage of Perspective Therapeutics with a Buy rating with a price target of $12, up from $8. The company is leading the next wave of radiopharmaceutical innovation, combining manufacturing readiness with cutting-edge molecular design to deliver precision oncology at scale, the analyst tells investors in a research note. Perspective's lead program VMT-alpha-NET has a promising interim phase 1/2B profile, and additional programs in melanoma and FAP offer upside, the firm added.

UBS

David Lai

Buy

downgrade

$18 -> $7

2025-11-21

Reason

UBS

David Lai

Price Target

$18 -> $7

2025-11-21

downgrade

Buy

Reason

UBS analyst David Lai lowered the firm's price target on Perspective Therapeutics to $7 from $18 and keeps a Buy rating on the shares.

UBS

David Lai

Buy

downgrade

$18 -> $7

2025-11-20

Reason

UBS

David Lai

Price Target

$18 -> $7

2025-11-20

downgrade

Buy

Reason

UBS analyst David Lai lowered the firm's price target on Perspective Therapeutics to $7 from $18 and keeps a Buy rating on the shares. The Q3 press release highlighted upcoming data updates in 1H26 for lead program VMT-alpha-NET, with the firm saying we should expect an additional 23 patients as early as Q1 as well as durability from existing patients. The firm added that it believes increased competition may impact commercial adoption of VMT-alpha-NET.

Oppenheimer

Outperform

maintain

$14 -> $13

2025-11-11

Reason

Oppenheimer

Price Target

$14 -> $13

2025-11-11

maintain

Outperform

Reason

Oppenheimer lowered the firm's price target on Perspective Therapeutics (CATX) to $13 from $14 and keeps an Outperform rating on the shares following the company's Q3 business update on Monday afternoon. The update follows recent positive results for VMT-alpha-NET presented at ESMO, with Perspective down 29% on the day, after competitor Sanofi (SNY)/Oranomed presented updated Alphamedix02 results with a 60% ORR in the same session. In Oppenheimer's view key differences between the studies make this a more competitive story than the headline numbers suggest, keeping the firm cautiously optimistic.

Oppenheimer

Outperform

maintain

$14

2025-09-15

Reason

Oppenheimer

Price Target

$14

2025-09-15

maintain

Outperform

Reason

Oppenheimer reiterated an Outperform rating and $14 price target on Perspective Therapeutics after the firm hosted the company's leadership team for an investor dinner last week. The firm said it came away with increased confidence that the VMT-alpha-NET update at ESMO on October 20 will build on prior results presented this summer at ASCO, while cautioning on setting a bar for response rates given the uncertainty on the length of follow-up for these patients. The 6mCi dose seeks to improve efficacy while preserving the safety margin or VMT-alpha-NET, and management seems confident in 5mCi as a potential go-forward dose in a registrational trial, the analyst tells investors in a research note.

B. Riley

Buy

maintain

$9 -> $12

2025-06-23

Reason

B. Riley

Price Target

$9 -> $12

2025-06-23

maintain

Buy

Reason

B. Riley raised the firm's price target on Perspective Therapeutics to $12 from $9 and keeps a Buy rating on the shares. The firm says sequential positive updates from Perspective drive the higher price target. It now sees an increased probabiliry of success for VMT-alpha-NET to deliver best-in-class efficacy and safety profile.

Valuation Metrics

The current forward P/E ratio for Perspective Therapeutics Inc (CATX.A) is -1.86, compared to its 5-year average forward P/E of -12.57. For a more detailed relative valuation and DCF analysis to assess Perspective Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.57

Current PE

-1.86

Overvalued PE

5.69

Undervalued PE

-30.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.90

Current EV/EBITDA

-0.33

Overvalued EV/EBITDA

7.76

Undervalued EV/EBITDA

-17.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

230.65

Current PS

350.46

Overvalued PS

735.75

Undervalued PS

-274.45

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CATX News & Events

Events Timeline

No data

News

9.0

01-09Globenewswire

Perspective Therapeutics Updates VMT-α-NET Trial Results, 39% Patient Response Rate Achieved

1.0

2025-12-18Globenewswire

Perspective Therapeutics CEO Thijs Spoor to Present at 2026 J.P. Morgan Healthcare Conference

4.0

2025-11-24Benzinga

Truist Securities Initiates Coverage on Perspective Therapeutics with a Buy Rating and Increases Price Target to $12

People Also Watch

Frequently Asked Questions

What is Perspective Therapeutics Inc (CATX) stock price today?

The current price of CATX is 2.84 USD — it has increased 1.07 % in the last trading day.

What is Perspective Therapeutics Inc (CATX)'s business?

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

What is the price predicton of CATX Stock?

What is Perspective Therapeutics Inc (CATX)'s revenue for the last quarter?

Perspective Therapeutics Inc revenue for the last quarter amounts to 209.00K USD, decreased -43.36 % YoY.

What is Perspective Therapeutics Inc (CATX)'s earnings per share (EPS) for the last quarter?

Perspective Therapeutics Inc. EPS for the last quarter amounts to -0.35 USD, increased 66.67 % YoY.

What changes have occurred in the market's expectations for Perspective Therapeutics Inc (CATX)'s fundamentals?

How many employees does Perspective Therapeutics Inc (CATX). have?

Perspective Therapeutics Inc (CATX) has 138 emplpoyees as of January 10 2026.

What is Perspective Therapeutics Inc (CATX) market cap?

Today CATX has the market capitalization of 211.12M USD.